• 664
  • 664

Xuan Jianwei

Director of Health Economics Research Institute, School of Pharmaceutical Sciences, Sun Yat-Sen University

Dr. Xuan obtained his Ph.D. in Health Economics and Master Degree in Medicine Policy and Market Management from School of Public Health, University of North Carolina at Chapel Hill and completed his medical degree in Shanghai Medical University, China.

With more than 20 years of teaching and research experience, Dr. Xuan have published extensively in clinical study, health economic, policy research, market access and outcomes research. He has established extensive professional network with global key opinion leaders and led numerous global policy forums, advisory boards, and government/payer panel discussions. He has delivered a range of lectures in the National Development and Reform Commission, Ministry of Health and Ministry of Human Resources and Social Security and provided support to policy research. He is current Chair of ISPOR Asia Consortium Advisory Committee. He also has rich experience in researching, teaching, Ph.D. advising and training of government officials, research fellows, and those who focus on the medical and health care service.

Dr. Xuan has more than 20 years of global business management and leadership experience in several multinational pharmaceutical companies such as Pfizer, GSK, etc. He has led multiple teams specialized in global health economic and market access and conducted researches on high impact clinical study, health policy, health economics, comparative effectiveness, outcomes research, mobile medical care, epidemiology and market access to support evidence-based decision-making process. His research results have been applied in many countries to support policy formulation in national health care, prescription drug reimbursement and government decision making. 

Before studying in the USA, he had worked as drug reviewer in China FDA for more than 6 years. Dr. Xuan is very familiar with drug development process, global drug regulation and registration affairs, and drug safety requirements. He also serves as advisor to pharmaceutical companies at home and abroad.